You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Drug target identification using CRISPRi/a screening

    SBC: BIOIO, LLC            Topic: 400

    ABSTRACT As phenotypic screening makes a comeback in drug discovery, its major issue is drug target identification. There aren’t good generalizable approaches to do target identification for compounds of interest. Identifying how a new drug works at the molecular level is critical for improving it, which is often needed to give it the best chance of ultimately being both safe and effective in pa ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Oleocanthal functional food products for breast cancer recurrence control

    SBC: Oleolive, LLC            Topic: 102

    SUMMARY Triple negative breast cancer (TNBC) represents 20% of the breast cancer (BC) cases in the US. TNBC patients have a poor recurrence-free, overall survival rate, and limited treatment options. The Mediterranean olive oil-rich diet is documented to reduce BC incidence. (-)-Oleocanthal (OC) is a natural phenolic exclusively occurring in extra-virgin olive oil (EVOO). It showed selective anti- ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. Multi-Modal Venus Clot Removal Device

    SBC: Caeli Vascular LLC            Topic: NHLBI

    ABSTRACTThis Phase I STTR application from Caeli Vascular, LLC entails a 12-month period focused on the development of a novel endovascular venous thrombectomy device. The PI is a vascular surgeon with biomedical research and entrepreneurship experience, and is supported by a team of highly qualified investigators, including a vascular biologist, neurosurgeon, veterinarian, biomedical engineer, me ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  4. Multi-fold increase in the production of pharmaceutical insulin with Microbial Stem Cell Technology

    SBC: ASIMICA, INC.            Topic: 300

    PROJECT SUMMARY / ABSTRACT The goal of this project is to demonstrate the feasibility of a novel technology that is expected to boost yields from pharmaceutical industrial insulin production by greater than four-fold over conventional methods. Higher yields will lower production costs, generating savings that will ultimately be passed onto the millions of diabetic patients who require daily insuli ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  5. Developing Real-time Interaction and Motion Tracking in Immersive Virtual Reality for Telerehabilitation

    SBC: Move LLC            Topic: 102

    Abstract Unceasing breakthroughs in technology will shape future healthcare diagnosis, treatment, and delivery. Telerehabilitation delivers rehabilitative healthcare remotely to overcome spatial, temporal and economic barriers. Effectiveness of telerehabilitation has been seen for patients with orthopedic and traumatic injuries, degenerative central nervous system disorders, and cardiovascular dis ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a New Treatment for Diabetic Wounds

    SBC: NUTRIWYO LLC            Topic: NIDDK

    Abstract: Non-healing wounds affect ~25% of people with diabetes and represent a primary cause of amputation of lower limbs, which is an enormous clinical problem and a substantial economic burden. Given the lack of approved agents that effectively aid in the healing of diabetic wounds, a major need exists for developing novel pharmacological agents for treating diabetic wounds. Chronic diabetic w ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  7. Novel insulin-sensitizing NASH/diabetes drugs.

    SBC: BIOIO, LLC            Topic: 300

    Obesity is associated with an increased risk of a number of chronic and progressive diseases and obesity- related metabolic diseases constitute a significant public health burden. The increased likelihood of developing insulin resistance and diabetes is probably the most commonly recognized risk of being obese. In addition, obesity is also associated with accumulation of lipid in the liver parench ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  8. Novel non-narcotic analgesic for acute and chronic pain

    SBC: South Rampart Pharma, LLC            Topic: 104

    Abstract Acute and chronic pain affect more than 50 million Americans and there is an enormous unmet need for safer pain relief. Although acetaminophen (ApAP) is among the medicines most commonly used for pain relief, hepatotoxicity is a risk and overdose is the most common cause of acute fulminant hepatic failure. Oxidation of ApAP to N-acetyl-p-benzoquinone imine (NAPQI) leads to hepatotoxicity. ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  9. A Deep Learning Model to Improve Pathologist Interpretation of Donor Kidney Biopsies

    SBC: PlatformSTL (DBA for NewVentureIQ LLC)            Topic: 400

    ABSTRACT More people die every year from kidney disease than breast or prostate cancer. Kidney transplantation is life-saving, yet the donor organ shortage and high organ discard rate contributes to 13 deaths daily among patients awaiting transplant. The decision to use or discard a donor kidney relies heavily on microscopic quantitation of chronic damage by pathologists. The current standard of c ...

    STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. Developing a Nutraceutical Product against Ototoxicity

    SBC: GATEWAY BIOTECHNOLOGY, INC.            Topic: NIDCD

    PROJECT SUMMARYDespite recent advances in cancer therapiesplatinum based drugs are still widely used for the treatment of solid tumorsA primary example is cisplatinwhich is frequently used to treat lungbladdertesticularand cervical cancersHoweverlimitations of this therapy include the development of drug resistance in cancer cells as well as severe side effectssuch as nephrotoxicity and neurotoxic ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government